Literature DB >> 28447181

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.

Yumei Ye1, Mandeep Bajaj2, Hsiu-Chiung Yang3, Jose R Perez-Polo1, Yochai Birnbaum4.   

Abstract

PURPOSE: We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice. (2) The effects can be augmented with saxagliptin (Saxa), a DDP4-inhibitor. (3) Dapa effect is possibly SGLT2-independent on cardiofibroblasts in vitro.
METHODS: Type 2 diabetic (BTBR ob/ob) and wild-type (WT) mice received vehicle, Dapa, or Dapa+Saxa for 8 weeks. Glucose tolerance test and echocardiogram were performed. Cardiofibroblasts from WT and BTBR hearts were incubated with Dapa and exposed to LPS.
RESULTS: Left ventricular ejection fraction (LVEF) was 81 ± 1% in the WT and 53 ± 1% in the T2D-cont mice. Dapa and Dapa+Saxa improved LVEF to 68 ± 1 and 74.6 ± 1% in the BTBR mice (p < 0.001). The mRNA levels of NALP3, ASC, IL-1β, IL-6, caspase-1, and TNFα were significantly higher in the BTBR compared to the WT hearts; and Dapa and Dapa+Saxa significantly attenuated these levels. Likewise, protein levels of NLRP3, TNFα, and caspase-1 were higher in the BTBR compared to the WT hearts and Dapa, and to a greater extent Dapa+Saxa, attenuated the increase in the BTBR mice. Collagen-1 and collagen-3 mRNA levels significantly increased in the BTBR mice and these increases were attenuated by Dapa and Dapa+Saxa. P-AMPK/total-AMPK ratio was significantly lower in the BTBR mice than in the WT mice. Dapa and Dapa+Saxa equally increased the ratio in the BTBR mice. This in vitro study showed that NALP3, ASC, IL-1β, and caspase-1 mRNA levels were higher in the BTBR cardiofibroblasts and attenuated with Dapa. The effect was AMPK-dependent and SGLT1-independent.
CONCLUSIONS: Dapa attenuated the activation of the inflammasome, fibrosis, and deterioration of LVEF in BTBR mice. The anti-inflammatory, anti-fibrotic effects are likely SGLT2- and glucose-lowering-independent, as they were replicated in the in vitro model. The effects on remodeling were augmented when Saxa was added to Dapa. Yet, adding Saxa to Dapa did not result in a greater effect on myocardial fibrosis and collagen levels.

Entities:  

Keywords:  DPP-4 inhibitor; Diabetes mellitus; Fibrosis; Inflammation; SGLT-2 inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28447181     DOI: 10.1007/s10557-017-6725-2

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  88 in total

Review 1.  Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation.

Authors:  Alan J Mouton; Xuan Li; Michael E Hall; John E Hall
Journal:  Circ Res       Date:  2020-03-12       Impact factor: 17.367

2.  Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.

Authors:  Manisha Gupte; Prachi Umbarkar; Hind Lal
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

Review 3.  SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials.

Authors:  Xiaoming Jia; Paras B Mehta; Yumei Ye; Mahboob Alam; Yochai Birnbaum; Mandeep Bajaj
Journal:  Curr Diab Rep       Date:  2018-07-11       Impact factor: 4.810

Review 4.  Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.

Authors:  Abdullah Kaplan; Emna Abidi; Ahmed El-Yazbi; Ali Eid; George W Booz; Fouad A Zouein
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

5.  Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.

Authors:  Anke C Fender; Sonja Kleeschulte; Svenja Stolte; Katja Leineweber; Markus Kamler; Johannes Bode; Na Li; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2020-01-07       Impact factor: 17.165

6.  What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.

Authors:  Jessica A Dominguez Rieg; Timo Rieg
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

7.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

8.  INT-777 attenuates NLRP3-ASC inflammasome-mediated neuroinflammation via TGR5/cAMP/PKA signaling pathway after subarachnoid hemorrhage in rats.

Authors:  Xiao Hu; Jun Yan; Lei Huang; Camila Araujo; Jun Peng; Ling Gao; Shengpeng Liu; Jiping Tang; Gang Zuo; John H Zhang
Journal:  Brain Behav Immun       Date:  2020-09-19       Impact factor: 7.217

Review 9.  Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors:  Utkarsh Ojha; Lenisse Reyes; Florence Eyenga; Diane Oumbe; Justyna Watkowska; Henock Saint-Jacques
Journal:  Am J Cardiovasc Drugs       Date:  2021-06-30       Impact factor: 3.571

Review 10.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.